Repligen (RGEN) News Today $126.88 -3.52 (-2.70%) Closing price 04:00 PM EasternExtended Trading$126.89 +0.01 (+0.01%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Repligen's (RGEN) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Monday.May 7 at 8:15 AM | marketbeat.comRepligen Corporation to Present at Upcoming May Investor ConferencesMay 7 at 7:30 AM | globenewswire.comBaird Financial Group Inc. Cuts Stake in Repligen Co. (NASDAQ:RGEN)Baird Financial Group Inc. cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 7.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 354,237 shares of the biotechnology companMay 7 at 6:14 AM | marketbeat.comBamco Inc. NY Lowers Position in Repligen Co. (NASDAQ:RGEN)Bamco Inc. NY reduced its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 4.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 160,227 shares of the biotechnology company's stock after selMay 7 at 5:58 AM | marketbeat.comAlyeska Investment Group L.P. Makes New Investment in Repligen Co. (NASDAQ:RGEN)Alyeska Investment Group L.P. bought a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 371,180 shares of the biotechnology company's stock, valuMay 6 at 5:30 AM | marketbeat.comSusquehanna Fundamental Investments LLC Takes Position in Repligen Co. (NASDAQ:RGEN)Susquehanna Fundamental Investments LLC bought a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,000 shares of the biotechnology company'May 6 at 4:21 AM | marketbeat.comRepligen's (RGEN) "Buy" Rating Reiterated at HC WainwrightMay 6 at 2:33 AM | americanbankingnews.comRepligen’s Strategic Growth and Resilience Drive Buy Rating with $180 Price TargetMay 5 at 7:03 AM | tipranks.comFY2025 EPS Estimates for Repligen Boosted by William BlairRepligen Co. (NASDAQ:RGEN - Free Report) - Analysts at William Blair increased their FY2025 earnings per share estimates for Repligen in a report issued on Wednesday, April 30th. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $1.68 per share forMay 4 at 8:11 AM | marketbeat.comQ2 Earnings Estimate for Repligen Issued By Leerink PartnrsRepligen Co. (NASDAQ:RGEN - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for shares of Repligen in a research note issued to investors on Tuesday, April 29th. Leerink Partnrs analyst P. Souda now anticipates that the biotechMay 4 at 7:15 AM | marketbeat.comQ2 Earnings Forecast for Repligen Issued By Leerink PartnrsMay 4 at 1:19 AM | americanbankingnews.comStifel Nicolaus Reaffirms Their Buy Rating on Repligen (RGEN)May 3, 2025 | theglobeandmail.comWilliam Blair Brokers Lower Earnings Estimates for RepligenRepligen Co. (NASDAQ:RGEN - Free Report) - William Blair decreased their Q2 2025 earnings per share (EPS) estimates for shares of Repligen in a research note issued to investors on Wednesday, April 30th. William Blair analyst M. Larew now forecasts that the biotechnology company will earn $0.41 pMay 3, 2025 | marketbeat.comRoyal Bank of Canada Cuts Repligen (NASDAQ:RGEN) Price Target to $189.00May 3, 2025 | americanbankingnews.comFY2025 EPS Estimates for Repligen Lifted by William BlairMay 3, 2025 | americanbankingnews.comRepligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On HealthcareMay 2, 2025 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), SAGE Therapeutics (SAGE) and Repligen (RGEN)May 2, 2025 | theglobeandmail.comDimensional Fund Advisors LP Raises Holdings in Repligen Co. (NASDAQ:RGEN)Dimensional Fund Advisors LP boosted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 28.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 580,485 shares of the biotechnology company's stock after buying an additMay 2, 2025 | marketbeat.comWilliam Blair Predicts Repligen's Q2 Earnings (NASDAQ:RGEN)May 2, 2025 | americanbankingnews.comRepligen (NASDAQ:RGEN) Upgraded to "Outperform" at Wolfe ResearchWolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research note on Tuesday.May 1, 2025 | marketbeat.comJim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’May 1, 2025 | insidermonkey.comRepligen (NASDAQ:RGEN) Releases Earnings Results, Beats Estimates By $0.04 EPSRepligen (NASDAQ:RGEN - Get Free Report) released its earnings results on Tuesday. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 earnings per share.May 1, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Shares Gap Down - What's Next?Repligen (NASDAQ:RGEN) Shares Gap Down - What's Next?May 1, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Updates FY 2025 Earnings GuidanceRepligen (NASDAQ:RGEN) updated its FY 2025 earnings guidance. The company provided EPS guidance of 1.630-1.720 for the period, compared to the consensus estimate of 1.710. The company also issued revenue guidance of $695.0 millionillion-$720.0 millionillion, compared to the consensus estimate of $700.8 millionillion.May 1, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Q1 2025 Earnings Call TranscriptMay 1, 2025 | msn.com7RGEN : Deep Dive Into Repligen Stock: Analyst Perspectives...May 1, 2025 | benzinga.comRGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff UncertaintyMay 1, 2025 | msn.comWolfe Research Upgrades Repligen (NASDAQ:RGEN) to "Outperform"May 1, 2025 | americanbankingnews.comRepligen (NASDAQ:RGEN) Upgraded to "Hold" at StockNews.comStockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Monday.April 30, 2025 | marketbeat.comRepligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock NewsApril 30, 2025 | gurufocus.comRepligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock NewsApril 30, 2025 | gurufocus.comFirst Light Asset Management LLC Trims Stock Position in Repligen Co. (NASDAQ:RGEN)First Light Asset Management LLC decreased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 50.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 82,455 shares of the biotechnology company's stock after selling 83,418April 30, 2025 | marketbeat.comRepligen’s Fair Valuation and Cautious Growth Outlook Lead to Hold RatingApril 30, 2025 | tipranks.comRepligen (NASDAQ:RGEN) Price Target Lowered to $190.00 at JPMorgan Chase & Co.April 30, 2025 | americanbankingnews.comRepligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds ExpectationsApril 30, 2025 | msn.comRepligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...April 30, 2025 | gurufocus.comRepligen Corporation (RGEN) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.comRepligen Non-GAAP EPS of $0.39 beats by $0.04, revenue of $169M beats by $5.25MApril 29, 2025 | seekingalpha.comRepligen Reports First Quarter 2025 Financial ResultsApril 29, 2025 | globenewswire.comNZS Capital LLC Boosts Position in Repligen Co. (NASDAQ:RGEN)NZS Capital LLC grew its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,694 shares of the biotechnology company's stoApril 29, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Increases Stock Position in Repligen Co. (NASDAQ:RGEN)T. Rowe Price Investment Management Inc. grew its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 474.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 159,057 shares of the biotechnology company's stock after purchasingApril 29, 2025 | marketbeat.comPinebridge Investments L.P. Boosts Stake in Repligen Co. (NASDAQ:RGEN)Pinebridge Investments L.P. lifted its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 42.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,110 shares of the biotechnology company's stock after buying an adApril 29, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Raised to "Hold" at StockNews.comApril 29, 2025 | americanbankingnews.comRepligen (RGEN) Q1 Earnings: What To ExpectApril 28, 2025 | msn.comTower Research Capital LLC TRC Has $967,000 Stock Holdings in Repligen Co. (NASDAQ:RGEN)Tower Research Capital LLC TRC grew its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 89.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,718 shares of the biotechnology company's stock after purchApril 28, 2025 | marketbeat.comMetLife Investment Management LLC Acquires 2,428 Shares of Repligen Co. (NASDAQ:RGEN)MetLife Investment Management LLC raised its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 8.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,774 shares of the biotechnology company's stApril 27, 2025 | marketbeat.comCanada Pension Plan Investment Board Makes New $792,000 Investment in Repligen Co. (NASDAQ:RGEN)Canada Pension Plan Investment Board acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,500 shares of the biotechnologApril 27, 2025 | marketbeat.comRepligen (RGEN) Projected to Post Earnings on TuesdayRepligen (NASDAQ:RGEN) will be releasing its Q1 2025 earnings before the market opens on Tuesday, April 29. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-4-29-repligen-co-stock/)April 27, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Acquired by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD lifted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 11.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,136,054 shares of the biotechnology company's stock afterApril 26, 2025 | marketbeat.comFirst Trust Advisors LP Has $41.10 Million Holdings in Repligen Co. (NASDAQ:RGEN)First Trust Advisors LP decreased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 285,561 shares of the biotechnologyApril 26, 2025 | marketbeat.com Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Media Mentions By Week RGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGEN News Sentiment▼0.480.64▲Average Medical News Sentiment RGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGEN Articles This Week▼419▲RGEN Articles Average Week Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biogen News United Therapeutics News Incyte News BioMarin Pharmaceutical News Exelixis News Neurocrine Biosciences News Exact Sciences News Halozyme Therapeutics News Madrigal Pharmaceuticals News Ionis Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGEN) was last updated on 5/7/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RGEN Stock Free RGEN Stock Alerts